Skip to main content

Advertisement

SpringerLink
Log in

Probiotic use in irritable bowel syndrome

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Over the past several years, a number of studies have addressed the role of specific strains of bacteria, or combinations thereof, to alleviate certain symptoms of irritable bowel syndrome (IBS). More importantly, the precise factors that contribute to this therapeutic effect, such as modulations in cytokine levels and alterations in colonic motility, are being clarified. This review serves to summarize the evidence for the use of probiotics in the treatment of IBS and to place this information in clinical context. Potential future developments and areas of possible research are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada: May 1, 2002. Available at: http://www.who. int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 6/13/06.

  2. Leahy SC, Higgins DG, Fitzgerald GF, van Sinderen D: Getting better with bifidobacteria. J Appl Microbiol 2005, 98:1303–1315. This article provides a basic microbiologic background on bifidobacteria before discussing their potential therapeutic roles.

    Article  PubMed  CAS  Google Scholar 

  3. Montrose DC, Floch M: Probiotics used in human studies. J Clin Gastroenterol 2005, 39:469–484. This is an encyclopedic compilation of all human trials published to that point. It is an excellent reference for those interested in the topic.

    Article  PubMed  Google Scholar 

  4. Hallen A, Jarstrand C, Pahlson C: Treatment of bacterial vaginosis with lactobacilli. Sex Transm Dis 1992, 19:146–148.

    Article  PubMed  CAS  Google Scholar 

  5. Anderson JW, Gilliland SE: Effects of fermented milk (yogurt) on containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr 1999, 18:43–50.

    PubMed  CAS  Google Scholar 

  6. Cash BD, Chey WD: Irritable bowel syndrome: A systematic review. Clin Fam Pract 2004, 6:647–669. An excellent overview of this common condition.

    Article  Google Scholar 

  7. Dhaliwal SK, Hunt RH: Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur J Gastroenterol Hepatol 2004, 16:1161–1166.

    Article  PubMed  Google Scholar 

  8. Dapoigny M, Bellanger J, Bonaz B, et al.: Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 2004, 16:995–1001.

    Article  PubMed  Google Scholar 

  9. Cain KC, Headstrom P, Jarrett ME, et al.: Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:124–132.

    Article  PubMed  Google Scholar 

  10. Galnek IM, Hays RD, Kilbourne A, et al.: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 229:654–660.

    Google Scholar 

  11. Thompson WG, Longsteth GF, Drossman DA: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl II):1143–1147.

    Google Scholar 

  12. Chey WY, Jin HO, Lee MH, et al.: Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001, 96:1499–1506.

    Article  PubMed  CAS  Google Scholar 

  13. Chang L, Munakata J, Mayer EA, et al.: Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000, 47:497–505.

    Article  PubMed  CAS  Google Scholar 

  14. Lawal A, Kern M, Sidhu H, et al.: Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006, 130:26–33.

    Article  PubMed  Google Scholar 

  15. Atkinson W, Lockhart S, Whorwell PJ, et al.: Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006, 130:34–43.

    Article  PubMed  CAS  Google Scholar 

  16. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel disease. Am J Gastroenterol 2000, 95:3503–3506.

    Article  PubMed  CAS  Google Scholar 

  17. Gwee KA, Collin SM, Read NW, et al.: Increased rectal mucosal expression of interleukin 1-β in recently acquired post-infectious irritable bowel syndrome. Gut 2003, 52:523–526.

    Article  PubMed  CAS  Google Scholar 

  18. Palsson OS, Morteau O, Bozymski EM, et al.: Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004, 49:1236–1243

    Article  PubMed  CAS  Google Scholar 

  19. Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804–811.

    Article  PubMed  CAS  Google Scholar 

  20. Reinders CI, Herluf M, Llung T, et al.: Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel disease. Clin Gastroenterol Hepatol 2005, 3:777–783.

    Article  PubMed  CAS  Google Scholar 

  21. Chadwick VS, Chen W, Shu D, et al.: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778–1783. This landmark article addresses the role of immune alterations in IBS.

    Article  PubMed  Google Scholar 

  22. Kristjansson G, Venge P, Wanders A, et al.: Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: Studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004, 53:1806–1812.

    Article  PubMed  CAS  Google Scholar 

  23. Barbara G, De Georgio R, Deng Y, et al.: Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001, 120:1729–1736.

    Article  PubMed  CAS  Google Scholar 

  24. H, Lindberg G, Nyberg B, et al.: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972–1979. This is the only study to date to examine full-thickness bowel specimens in patients with IBS.

    Article  Google Scholar 

  25. Barbara G, Stanghellini V, De Giorgio, et al.: Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006, 18:6–17.

    Article  PubMed  CAS  Google Scholar 

  26. Simon GL, Gorbach SL: Intestinal flora in health and disease. Gastroenterology 1984, 86:174–193.

    PubMed  CAS  Google Scholar 

  27. D’Souza AL, Rajkumar C, Cooke J, et al.: Probiotics in prevention of antibiotic associated diarrhea. BMJ 2002, 324:1361–1366. This well-performed meta-analysis helps to synthesize the data on this topic.

    Article  PubMed  Google Scholar 

  28. Szajewska H, Mrukowicz J: Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther 2005, 22:365–372.

    Article  PubMed  CAS  Google Scholar 

  29. Allen SJ, Okoko B, Martinez E, et al.: Probiotics for treating infections diarrhea. Cochrane Database Syst Rev 2004, CD003408.

  30. Tursi A, Brandimarte G, Giorgetti GM, et al.: Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2004, 10:CR662-CR666.

    PubMed  Google Scholar 

  31. Nista EC, Candelli M, Cremonini M, et al.: Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2004, 20:1181–1188.

    Article  PubMed  CAS  Google Scholar 

  32. Furrie E, MacFarlane E, Kennedy A, et al.: Symbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005, 54:242–249.

    Article  PubMed  CAS  Google Scholar 

  33. Kruis W, Fric P, Pokrotnieks J, et al.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617–1623.

    Article  PubMed  CAS  Google Scholar 

  34. O’Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541–551. This is the first article to look at the effect of probiotics on serum cytokine levels in IBS patients. It is the benchmark by which future studies will be judged.

    Article  PubMed  Google Scholar 

  35. Tsuchiya J, Barreto R, Okura R, et al.: Single-blind followup study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004, 5:169–174.

    Article  PubMed  CAS  Google Scholar 

  36. Kajander K, Hatakka K, Poussa T, et al.: A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005, 22:387–394.

    Article  PubMed  CAS  Google Scholar 

  37. Kim HJ, Vasquez-Roque MI, Camilleri M, et al.: A randomized controlled trial of a probiotic combination VSL #3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005, 17:687–696. A well-conducted study that addresses physiologic changes and symptoms.

    Article  PubMed  CAS  Google Scholar 

  38. Bausserman M, Michail S: The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind placebo control trial. J Pediatr 2005, 147:197–201.

    Article  PubMed  Google Scholar 

  39. Niv E, Naftali T, Hallak R, et al.: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study. Clin Nutr 2005, 24:925–931.

    Article  PubMed  Google Scholar 

  40. Bittner AC, Corffut RM, Stranahan MC: Prescript-AssistTM probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 2005, 27:755–761.

    Article  PubMed  Google Scholar 

  41. Patel DM, Stason WB, Legedza A, et al.: The placebo effect in irritable bowel trials: a meta-analysis. Neurogatroenterol Motil 2005, 17:332–340.

    Article  CAS  Google Scholar 

  42. Nobaek S, Johansson ML, Molin G, et al.: Alteration in intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231–1238.

    Article  PubMed  CAS  Google Scholar 

  43. Borish L, Rosenwasser LJ: Cytokines in allergic inflammation. In Middleton’s Allergy: Principles and Practice, edn 6. Edited by Yunginger J, Busse W, Bochner B, et al. Philadelphia: Mosby, Inc.; 2003:144–145.

    Google Scholar 

  44. McCarthy J, O’Mahony L, O’Callaghan L, et al.: Double blind, placebo controlled trail of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003, 52:975–980.

    Article  PubMed  CAS  Google Scholar 

  45. O’Sullivan MA, O’Moran CA: Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32:294–301.

    Article  PubMed  CAS  Google Scholar 

  46. Snelling A: Effects of probiotics on the gastrointestinal tract. Curr Opin Infect Dis 2005, 18:420–426.

    Article  PubMed  Google Scholar 

  47. Asahara T, Shimizu K, Nomoto K, et al.: Probiotic bifidobacteria protect mice from lethal infection with shiga toxin-producing Escherecia coli O157:H7. Infect Immun 2004, 72:2240–2247.

    Article  PubMed  CAS  Google Scholar 

  48. Sheil B, McCarthy J, O’Mahony L, et al.: Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004, 53:694–700.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Naval Medical Center, 8901 Wisconsin Avenue, Bldg. 9, 20889, Bethesda, MD, USA

    Patrick Young MD

Authors
  1. Patrick Young MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brooks D. Cash MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Young MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, P., Cash, B.D. Probiotic use in irritable bowel syndrome. Curr Gastroenterol Rep 8, 321–326 (2006). https://doi.org/10.1007/s11894-006-0053-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-006-0053-1

Keywords

Search

Navigation